Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
Contract data analysis service using the “HIGOMARI®” multivariate analysis methodContract analytical testing service using a range of advanced analytical instruments
Applicable field (uses covered by this announcement)
Biological genetic resources business, mainly plant genetic resources, and the development of functional foods
Launch dateContract data analysis service: began in January 2025 (actual); contract analytical testing service: began in April 2025 (actual)
Impact on Business Performance
The impact on results for the fiscal year ending March 2027 will be extremely limited, and the company has determined that it is not necessary to incorporate it into its earnings forecast.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Contract data analysis service using the “HIGOMARI®” multivariate analysis method, Contract analytical testing service using a range of advanced analytical instruments |
| Launch date | Contract data analysis service: began in January 2025 (actual); contract analytical testing service: began in April 2025 (actual) |
| Applicable area | Biological genetic resources business, mainly plant genetic resources, and the development of functional foods |
| Impact on Business Performance | The impact on results for the fiscal year ending March 2027 will be extremely limited, and the company has determined that it is not necessary to incorporate it into its earnings forecast. |
Items this document does not state (14)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following a review of the future direction of the biological genetic resources business with a view to commercializing it, the company will further strengthen its focus on priority areas, including the development of functional foods.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.